Canada markets open in 8 hours 34 minutes
  • S&P/TSX

    19,969.19
    -4.03 (-0.02%)
     
  • S&P 500

    3,963.51
    +29.59 (+0.75%)
     
  • DOW

    33,781.48
    +183.56 (+0.55%)
     
  • CAD/USD

    0.7358
    -0.0002 (-0.02%)
     
  • CRUDE OIL

    72.15
    +0.69 (+0.97%)
     
  • BTC-CAD

    23,399.34
    +403.91 (+1.76%)
     
  • CMC Crypto 200

    405.98
    +11.30 (+2.86%)
     
  • GOLD FUTURES

    1,809.40
    +7.90 (+0.44%)
     
  • RUSSELL 2000

    1,818.29
    +11.39 (+0.63%)
     
  • 10-Yr Bond

    3.4910
    0.0000 (0.00%)
     
  • NASDAQ futures

    11,685.75
    +40.25 (+0.35%)
     
  • VOLATILITY

    22.29
    -0.39 (-1.72%)
     
  • FTSE

    7,472.17
    -17.02 (-0.23%)
     
  • NIKKEI 225

    27,926.04
    +351.61 (+1.28%)
     
  • CAD/EUR

    0.6954
    -0.0012 (-0.17%)
     

COVID shot drives CanSinoBIO's first six-month profit since at least 2019

FILE PHOTO: China's vaccine specialist CanSino Biologics Inc in Tianjin

BEIJING (Reuters) - Chinese vaccine maker CanSino Biologics Inc (CanSinoBIO) said on Friday it had returned to operating profit of 802.3 million yuan ($123.79 million) in the first six months of 2021, driven by use of its COVID-19 shot. That compared with 123.0 million yuan of operating loss in the same period a year ago, CanSinoBIO said in a filing in the Hong Kong stock exchange. It marks the first six-month profit since at least 2019. The firm is yet to achieve full-year profits since it went public in 2018 in Hong Kong.

It reported 937.1 million yuan profit and total comprehensive income for the first six months of 2021. Its single-dose COVID-19 shot, named Ad5-nCoV, has been approved for use in countries including China, Mexico, Pakistan and Chile. The vaccine approvals were one of the major drivers for the sixth-month profit, CanSinoBIO said.

($1 = 6.4813 Chinese yuan renminbi)

(Reporting by Roxanne Liu and Ryan Woo; Editing by Catherine Evans)